🤒 Herpes zoster causes rare urinary issue in 10yo girl

Herpes zoster was documented to cause acute urinary retention in a young patient. This happened to a previously healthy 10-year-old Japanese girl at IMS Fujimi General Hospital in Saitama, Japan. Symptoms started nine days before admission, and she was admitted on the 10th day after symptom onset. This rare presentation highlights the need to consider herpes zoster when urinary symptoms appear with a vesicular rash. The patient was ultimately diagnosed and discharged on day 7 of hospitalization.

🔬 Higher BMI messes with RA drug effectiveness

Adults with rheumatoid arthritis showed worse clinical responses to JAK inhibitors when they had a higher Body Mass Index. This finding came from a meta-analysis of 16 phase 3 randomized controlled trials involving 11,883 patients across various weight categories. The research, published on August 3 in The Lancet Rheumatology, showed reduced ACR20 response in those with overweight or obesity classes 2 and 3. This suggests obesity significantly modifies how well these treatments work for RA patients. Future trials need to properly represent the full BMI spectrum to ensure treatment generalizability. 🔬

🧪 Yeast engineered to make cancer drug precursors

Researchers in China successfully engineered baker’s yeast to produce a precursor compound for two essential cancer medicines. The team, led by Yating Hu and Luqi Huang at Capital Medical University in Beijing, achieved this by reconstructing a 45-enzyme biosynthetic pathway inside the yeast. This process allows the yeast to generate the immediate precursor to etoposide from glucose in a simple three-day fermentation. This microbial synthesis bypasses the need for extracting podophyllotoxin from an endangered Himalayan plant. While scaling remains a future challenge, the study offers a new, efficient route for drug production. 🧪

🔬 Biologic choice impacts psoriasis to arthritis risk

A study found that specific biologic drugs affect the risk of psoriasis progressing to psoriatic arthritis (PsA). Researchers observed this in 393 adults treated in Greece between January 2008 and June 2025. While 22% developed PsA overall, TNF inhibitors showed higher risk compared to IL-17, IL-23, and IL-12/23 inhibitors. These IL-targeting drugs showed significantly lower risks of PsA development than TNF inhibitors. Future prospective studies are needed to validate these interesting findings.

🔬 Maintenance therapy vs surveillance in mCRC: what's the tea?

Maintenance therapy showed longer overall survival than active surveillance for metastatic colorectal cancer patients who controlled their disease after bevacizumab chemo. The study, done at a single center, looked at 94 patients between January 2015 and December 2025. The maintenance group had a median OS of 24.8 months versus 18.0 months in the surveillance group. However, this survival benefit disappeared when adjusting for initial prognostic factors. Future research needs to confirm these findings given the study's retrospective nature. 🧐

🩺 Fast DNA test could save newborn hearing

Rapid genetic screening can identify newborns at high risk for permanent hearing loss from certain antibiotics. This was studied by Erasmus University Medical Center in Rotterdam, Netherlands, using the MT-RNR1 gene variant. In a 2022 trial of 751 newborns, results were available in under 26 minutes. This shows pharmacogenetics can work in time-critical ICU settings. Now, official recommendations are being updated globally for better newborn care. 👶

🦴 Denosumab beats Alendronate for bone density in RA patients

Denosumab showed better improvement in lumbar spine bone mineral density compared to alendronate for postmenopausal women with RA on glucocorticoids. The study, conducted in China, involved 295 patients between January 2018 and December 2023. Denosumab patients saw a mean difference of 0.444% in BMD after one year. While denosumab had a numerically higher fracture rate at 8.1% versus 1.6%, this difference wasn't statistically significant. Further large-scale studies are needed to confirm the comparative effectiveness of these treatments.

🩺 Weight loss meds help breast cancer survivors?

A phase 2 trial suggested that adding a non-GLP-1 weight-loss drug could help some breast cancer survivors reach their target weight. This study was conducted by researchers at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore. The trial enrolled 55 women, and 42% of those who needed extra help successfully reached a 5% weight loss threshold by six months. This intervention was used for women who couldn't lose weight enough through lifestyle changes alone. Larger studies are needed to confirm this threshold-based approach for prescribing these medications. 🩺

🔬 Ubiquitin code unlocks new drug frontiers

Protein-degrading drugs, leveraging the cell’s ubiquitin system, are revolutionizing medicine. FDA approved Veppanu for breast cancer and Zenbexus for multiple myeloma in May and August this year. These drugs use ubiquitin, a small protein, to selectively destroy problematic proteins within cells. Understanding the complex 'ubiquitin code' is helping design targeted therapies for cancer and more. Researchers anticipate a major shift in the pharmaceutical industry due to this research. 🧬

🩺 Antiseizure med linked to higher clot risk with DOACs

New data suggests levetiracetam might increase the risk of thromboembolic events when used with DOACs. This was found in a retrospective study involving over 9000 adults with epilepsy across 165 healthcare organizations. The study compared levetiracetam against lamotrigine or lacosamide, finding a nearly twofold higher risk for the former. This prompts caution since levetiracetam was previously thought to have low drug interaction potential. Clinicians should actively review ASM choice to manage anticoagulation safety going forward. 🩺

🔥 Nivin Pauly's film hits big box office numbers

Nivin Pauly's film, Bethlehem Kudumba Unit, is performing very strongly at the ticket windows. The Malayalam film stars Mamitha Baiju and is currently doing well across India. In just 72 hours, it recovered nearly 70% of its 30 crore budget. On Sunday, August 23, day 3, it earned between 8.5 to 9 crore. The film aims for a total net collection of 60 crore to be declared a hit. 🚀